Brind.
  1. Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.

Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.

1 report, 1 independent Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Adagene Inc. presented data regarding its ADG126 therapy at a CSCO meeting, with mentions of locations including Jinan and Suzhou.

Who's involved

What this event is mainly about
JinanSuzhou

Keep exploring

Part of

Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.

Also in this story

All 5 developments

The entities involved

  • Jinan

    capital of Shandong province, China

    Nothing else this week.

  • Suzhou

    prefecture-level city in Jiangsu, China, former capital of the kingdom of Wu

    Nothing else this week.

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAdagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China SAN DIEGO and SUZHOU, China, Sept. 05, 2025 (GLOBE NEWSWIRE) --